









A**B**

C

A673

D

KDM1A**TC252****KDM1B****ES-2****FLI**

Supplementary Figure S4: Doxorubicin and GSK-LSD1 have no effect on KDM1A mRNA and protein levels.

Relative mRNA expression levels of KDM1A, KDM1B and EWS/FLI (Type 1) following treatment with the indicated concentrations of (A) doxorubicin or (B) GSK-LSD1 for 48hrs. Data represents mean \pm SEM expression from three-five independent experiments. (C) Western blot analysis of KDM1A, KDM1B and FLI protein levels in A673, TC252 and ES-2 Ewing sarcoma cells following treatment with the indicated concentrations of GSK-LSD1, doxorubicin or AraC for 48hrs. (D) Quantification of protein levels (densitometry) of cells treated as in (C). Protein normalized to α -Tubulin (loading control) and vehicle (DMSO) control. Data represents mean \pm STDEV from two independent experiments. Cell lines are ranked in order of SP-2509 sensitivity. Asterisks denote statistical significance (* $P < 0.05$, ** $P < 0.01$, *** $P < 0.001$).